Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOLFIRI in Second-Line Advanced Pancreatic Cancer
NCT01543412Phase 2Completed
- Sponsor
- Fondazione Giscad per la Ricerca sui Tumori
- Start
- Jan 2010
- Primary completion
- Jun 2011
- Modality
- Nanoparticles, Monoclonal Antibodies, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab in pancreatic adenocarcinoma (PDAC), sponsored by Fondazione Giscad per la Ricerca sui Tumori. Primary endpoint: Overall Response Rate at 2 years. Started Jan 2010; status: completed.
02
Drugs
irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT01543412.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01543412.